Ascend (Drug Discovery) Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
116
- Latest Deal Type
-
Early Stage VC
- Investors
-
14
Ascend (Drug Discovery) General Information
Description
Provider of advanced therapy development and manufacturing services intended to support the creation and commercialization of biologic treatments. The company offers expertise in gene therapies, immunotherapies, oncolytics, and vaccines, along with integrated chemistry, manufacturing, and controls capabilities and fill-finish operations, enabling advanced therapeutic developers to progress from research to commercial production with improved scalability and regulatory alignment.
Contact Information
Website
www.ascend-adv.comCorporate Office
- 9800 Medical Center Drive
- Building D
- Rockville, MD 20850
- United States
Corporate Office
- 9800 Medical Center Drive
- Building D
- Rockville, MD 20850
- United States
Ascend (Drug Discovery) Timeline
Ascend (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 12-Nov-2024 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 08-May-2023 | Completed | Startup | |||
| 1. Early Stage VC | 01-Dec-2021 | $15M | $15M | Completed | Startup |
Ascend (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A2 | ||||||||
| Series A2 | ||||||||
| Series A | ||||||||
| Series A | ||||||||
| Series A | 55,520,832 | $0.000013 | $1.3 | $1.3 | 1x | $1.3 | 45.67% | |
| Series Seed | 15,000,000 | $0.000013 | $0.96 | $0.96 | 1x | $0.96 | 12.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ascend (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ascend (Drug Discovery) Patents
Ascend (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4752226-A1 | Plasmid system for aav production | Pending | 28-Nov-2024 | ||
| WO-2026119714-A2 | Plasmid system for aav production | Pending | 28-Nov-2024 | ||
| WO-2026119714-A3 | Plasmid system for aav production | Pending | 28-Nov-2024 | ||
| WO-2026109693-A1 | Method for improved aav production | Pending | 21-Nov-2024 | ||
| WO-2025238067-A1 | Novel vector system for aav production | Pending | 15-May-2024 | C12N15/86 |
Ascend (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ascend (Drug Discovery) Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ajinomoto Group Ventures | Corporate Venture Capital | Minority | ||
| DCVC | Venture Capital | Minority | ||
| EW Healthcare Partners | Growth/Expansion | Minority | ||
| 4BIO Capital | Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority |
Ascend (Drug Discovery) Acquisitions (3)
Ascend (Drug Discovery)’s most recent deal was a Merger/Acquisition with Advanced Bioscience Laboratories. The deal was made on 06-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Advanced Bioscience Laboratories | 06-Nov-2024 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Beacon Therapeutics (GMP Manufacturing Capacity in Alachua, Florida) | 01-Apr-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Freeline Therapeutics (Biotechnology) | 10-Feb-2023 | Merger/Acquisition | Drug Discovery |
Ascend (Drug Discovery) Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Advanced Bioscience Laboratories | Rockville, MD | 1961 |
Ascend (Drug Discovery) FAQs
-
When was Ascend (Drug Discovery) founded?
Ascend (Drug Discovery) was founded in 2021.
-
Where is Ascend (Drug Discovery) headquartered?
Ascend (Drug Discovery) is headquartered in Rockville, MD.
-
What is the size of Ascend (Drug Discovery)?
Ascend (Drug Discovery) has 116 total employees.
-
What industry is Ascend (Drug Discovery) in?
Ascend (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Ascend (Drug Discovery) a private or public company?
Ascend (Drug Discovery) is a Private company.
-
What is Ascend (Drug Discovery)’s current revenue?
The current revenue for Ascend (Drug Discovery) is .
-
How much funding has Ascend (Drug Discovery) raised over time?
Ascend (Drug Discovery) has raised $152M.
-
Who are Ascend (Drug Discovery)’s investors?
Ajinomoto Group Ventures, DCVC, EW Healthcare Partners, 4BIO Capital, and Abingworth are 5 of 14 investors who have invested in Ascend (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
